Search

Search Constraints

You searched for: Author/Creator Harrison, Simon

Search Results

6. Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study. (15th February 2017)

9. Australia and New Zealand Transplant and Cellular Therapies COVID‐19 vaccination consensus position statement. Issue 8 (22nd August 2021)

10. Imaging of patients with multiple myeloma and associated plasma cell disorders: consensus practice statement by the Medical Scientific Advisory Group to Myeloma Australia. Issue 10 (18th October 2021)